CSS
AGRX

Cubist Systematic Strategies’s Agile Therapeutics AGRX Stock Holding History

Cubist Systematic Strategies’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-34
Closed -$141K – 3176
2021
Q1 		$141K Buy
+34
New +$184K ﹤0.01% 2576
2020
Q4 		– Sell
-26
Closed -$160K – 2768
2020
Q3 		$160K Sell
26
-6
-19% -$34.4K ﹤0.01% 2192
2020
Q2 		$178K Buy
32
+6
+23% +$31.2K ﹤0.01% 2075
2020
Q1 		$96K Buy
+26
New +$149K ﹤0.01% 1917
2017
Q1 		– Sell
-1
Closed -$15K – 1923
2016
Q4 		$15K Buy
+1
New +$14K ﹤0.01% 1643

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cubist Systematic Strategies's AGRX Position: Q2 2021 in Review

Cubist Systematic Strategies sold out of Agile Therapeutics (AGRX) in Q2 2021, closing a stake of 34 shares — an estimated $141K sold.

Cubist Systematic Strategies first reported a position in AGRX in Q4 2016 and held it in 5 quarters. The position peaked at $178K in Q2 2020. 64 funds tracked by Wall St. Rank hold AGRX as of Q2 2021.

  • Cubist Systematic Strategies reported no remaining Agile Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Cubist Systematic Strategies sold 34 Agile Therapeutics shares in Q2 2021, an estimated $141K.
  • Cubist Systematic Strategies first reported a position in Agile Therapeutics in Q4 2016 and held it in 5 quarters.
  • Cubist Systematic Strategies's Agile Therapeutics position peaked at $178K in Q2 2020.
  • 64 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2021.

Based on Cubist Systematic Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.